Evaluation of Left Ventricular Functions after Aortic Valve Replacement in a Specific Young Male Patient Population with Pure Aortic Insufficiency or Aortic Stenosis: 5-Years Follow-up
Background. The aim of this study was to evaluate the left ventricular functions and the regression of left ventricular hypertrophy after aortic valve replacement (AVR) in young male patients with pure aortic stenosis or aortic insufficiency with no additional disease.
Methods. Young male patients who underwent AVR because of pure aortic stenosis (AS = 68) and insufficiency (AI = 70) were enrolled in the study. The mean age was 23.2 ± 1.3 and 22.6 ± 1.6 years, respectively. The follow-up time was 5 years. The parameters checked by transthoracic echocardiography were interventricular septum diastolic thickness, left ventricular posterior wall diastolic thickness, left ventricular end-diastolic diameter, left ventricle mass, left ventricle mass index, ejection fraction, and peak aortic gradient. Relative ventricle wall thickness was also calculated. Both groups values from the preoperative, postoperative sixth month, second year, and fifth year time intervals were compared.
Results. In the AS group, the preoperative left ventricular ejection fraction (%) value of 53.68 ± 5.04 increased to 63.24 ± 4.11 at the end of the fifth year. In the AI group, the preoperative left ventricular ejection fraction (%) value of 48.40 ± 3.56 increased to 59.77 ± 2.75 at the end of the fifth year. The other left ventricular geometric parameters were also compared within each group. At the end of the fifth year, there were significant and positive changes in each group.
Conclusion. The regression of the left ventricular parameters is a process that occurs over many years following the correction of the primary hemodynamic abnormality. Although the results were similar in the AI and AS group, in the AS group the remodeling process had earlier results than in the AI group.
Aurigemma GP, Silver KH, McLaughlin M, et al. 1994. Impact of chamber geometry and gender on left ventricular systolic function in patients >60 years of age with aortic stenosis. Am J Cardiol 74:794-8.nBech-Hanssen O, Wallentin I, Houltz E, et al. 1999. Gender differences in patients with severe aortic stenosis: impact on preoperative left ventricular geometry and function, as well as early postoperative morbidity and mortality. Eur J Cardiothorac Surg 15:24-30.nBenjamin EJ, Levy D. 1999. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 317:168-75.nBonow RO, Dodd JT, Maron BJ, et al. 1988. Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for aortic regurgitation. Circulation 78:1108-20.nDevereux RB, de Simone G, Ganau A, et al. 1994. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequences and prognostic implications. J Hypertens Suppl 12:S117-27. Review.nFlachskampf FA, Daniel WG. 2004. Aortic valve stenosis. Internist 45:1281-90.nGaasch WH, Carroll JD, Levine HJ, et al. 1983. Chronic aortic regurgitation: prognostic value of left ventricular end-systolic dimension and end-diastolic radius/thickness ratio. J Am Coll Cardiol 1:775-82.nGaudino M, Alessandrini F, Glieca F, et al. 2005. Survival after aortic valve replacement for aortic stenosis: does left ventricular mass regression have a clinical correlate. Eur Heart J 26:51-7.nHwang MH, Hammermeister KE, Oprian C, et al. 1989. Preoperative identification of patients likely to have left ventricular dysfunction after aortic valve replacement. Circulation 80:165-176.nJin XY, Gibson DG, Pepper JR. 1995. Early changes in regional and global left ventricular function after aortic valve replacement: comparison of crystalloid, cold blood, and warm blood cardioplegias. Circulation 92(9 suppl):II155-62.nJin XY, Zhang ZM, Gibson DG, Yacoub MH, Pepper JR. 1996. Effects of valve substitute on changes in left ventricular function and hypertrophy after aortic valve replacement. Ann Thorac Surg 62:683-90.nKrayenbuehl HP, Hess OM, Monrad ES, et al. 1989. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 79:744-55.nLamb HJ, Beyerbacht HP, de Roos A, et al. 2002. Left ventricular remodeling early after aortic valve replacement: differential effects on diastolic function in aortic valve stenosis and aortic regurgitation. J Am Coll Cardiol 40:2182-8.nLevy D, Garrison RJ, Savage DD, et al. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-6.nLund O. 1990. Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis. Reasons for earlier operative intervention. Circulation 82:124-39.nLund O, Emmertsen K, Dorup I, et al. 2003. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J 24:1437-46.nLund O, Kristensen LH, Baandrup U, et al. 1998. Myocardial structure as a determinant of pre and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis. Eur Heart J 19:1099-108.nLund O, Magnussen K, Knudsen M, et al. 1996. The potential for normal long-term survival and morbidity rates after valve replacement for aortic stenosis. J Heart Valve Dis 5:258-67.nLund O, Vaeth M. 1987. Prediction of late results following valve replacement in aortic stenosis. Seventeen years of follow-up examined with the Cox regression analysis. Thorac Cardiovasc Surg 35:295-303.nMonrad ES, Hess OM, Murakami T, et al. 1988. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 77:1345-55.nOrsinelli DA, Aurigemma GP, Battista S, et al. 1993. Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis. J Am Coll Cardiol 22:1679-83.nRoman MJ, Klein L, Devereux RB, et al. 1989. Reversal of left ventricular dilatation, hypertrophy, and dysfunction by valve replacement in aortic regurgitation. Am Heart J 118:553-63.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).